Bepotastine Besilate Nasal Sprays in the Treatment of Seasonal Allergic Rhinitis (SAR)
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
This study will examine dose ranging characteristics of bepotastine besilate nasal spray
compared to placebo nasal spray in 600 male or female subjects 12 years of age and older with
active seasonal allergic rhinitis (SAR) and a demonstrated history of allergic sensitivity to
Mountain Cedar pollen for at least 2 years prior to the study.